ストックスクリーナーアプリを入手
13.40
2.33%
-0.3355
前日終値:
$13.74
開ける：
$13.59
24時間の取引高:
220.07K
Relative Volume:
0.22
時価総額：
$591.16M
収益：
-
当期純損益:
$-168.05M
株価収益率:
-2.613
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
-2.47%
1か月 パフォーマンス:
+10.18%
6か月 パフォーマンス:
-78.72%
1年 パフォーマンス:
-75.15%
1日の値動き範囲:
$13.21
$13.71
1週間の範囲:
$13.21
$14.39
52週間の値動き範囲:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
13.37 | 591.16M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.51 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.78 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
541.80 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.49 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.26 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
FY2025 Earnings Forecast for KROS Issued By Leerink Partnrs - MarketBeat
Q2 EPS Estimate for Keros Therapeutics Increased by Analyst - MarketBeat
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Scotiabank Adjusts Price Target for Keros Therapeutics (KROS) | - GuruFocus
KROS: ADAR1 Capital Opposes Board Re-election at Keros Therapeutics | KROS Stock News - GuruFocus
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth - Stock Titan
Keros Therapeutics (KROS) Price Target Cut to $26 by Scotiabank - GuruFocus
Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsKROS - ACCESS Newswire
Keros Therapeutics CEO to Speak at Healthcare Conference - TipRanks
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference - The Manila Times
Voya Investment Management LLC Decreases Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Braidwell LP - MarketBeat
William Blair Has Negative Forecast for KROS Q2 Earnings - MarketBeat
Q2 EPS Forecast for Keros Therapeutics Lowered by Analyst - MarketBeat
Leerink Partnrs Has Negative Estimate for KROS Q2 Earnings - MarketBeat
DAFNA Capital Management LLC Purchases 56,562 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Investors who lost money on Keros Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationKROS - ACCESS Newswire
Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified - simplywall.st
Barclays PLC Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
JPMorgan Chase & Co. Acquires Significant Stake in Keros Therapeutics Inc. - GuruFocus
Alkeon Capital Management LLC Trims Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Reinforces Commitment to Maximizing Stockholder Value - The Manila Times
Keros Therapeutics Urges Stockholders to Support Board Nominees Amid ADAR1 Capital Management's Recent Communications - Nasdaq
ADAR1 Capital Management urges Keros Therapeutics for board change - Seeking Alpha
Keros Therapeutics Stockholder ADAR1 Seeks Business Restructuring Alleging Prolonged Underperformance - marketscreener.com
ADAR1 Capital Management Calls For Keros Therapeutics To Restructure Business, Reduce Headcount - marketscreener.com
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders | KROS Stock News - Stock Titan
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - marketscreener.com
Keros Therapeutics stock target cut to $25 at H.C. Wainwright By Investing.com - Investing.com India
Keros Therapeutics stock target cut to $25 at H.C. Wainwright - Investing.com
KROS Stock Target Cut by Analyst Amid Trial Setback | KROS Stock News - GuruFocus
Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Wells Fargo & Company MN Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
MetLife Investment Management LLC Purchases 1,027 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics Reports Strong Q1 2025 Results - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Tower Research Capital LLC TRC - MarketBeat
Boxer Capital Management LLC Invests $3.96 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Keros Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
KROS Reports Strong Q1 Earnings Boosted by License Agreement | KROS Stock News - GuruFocus
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results - The Manila Times
Keros Therapeutics Swings to Massive $148M Profit as Phase 1 Trial Hits Key Goals - Stock Titan
(KROS) Long Term Investment Analysis - news.stocktradersdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat
TCG Crossover Management LLC Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Darwin Global Management Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Nebula Research & Development LLC Has $1.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
Keros Therapeutics Inc (KROS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
| GORDON CARL L | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
4.19%
0.27%
大文字化:
|
ボリューム (24 時間):